Skip to main content

Table 2 Cox models were used to estimate the effect of different anti-hypertensive therapies on infectious, inflammatory and structural outcomes

From: Renin Angiotensin system-modifying therapies are associated with improved pulmonary health

 

Infectious (N = 21,523)

Inflammatory (N = 50,449)

Structural (N = 42,615)

ACE-I vs Control

Model 1 (Initial Drug)

 HR

0.886

0.924

0.865

 95%CI

0.859–0.886

0.906–0.942

0.847–0.885

  p

<0.0001

<0.0001

<0.0001

 NNT

240

156

104

Model 2 (Drug duration)

 Est

−0.0041

−0.0034

−0.031

  p

<0.0001

<0.0001

<0.0001

ARB vs Control

Model 1 (Initial Drug)

 HR

0.957

0.970

0.900

 95%CI

0.914–1.009

0.940–1.001

0.868–0.933

  p

0.1067

0.0568

<0.0001

 NNT

637

395

140

Model 2 (Drug duration)

 Est

−0.0050

−0.0033

−0.036

  p

<0.0001

<0.0001

<0.0001

  1. Model 1 uses the first drug prescribed and follows the incidence of diagnosis up until the patient stops taking the medication. Model 2 takes into account the duration of the treatment in order to compare to emergence of disease. Diabetic-status, Flu Vaccine and Statin use are corrected for in each analysis comparing anti-hypertensive therapy. The number needed to treat (NNT) was also calculated for ACE-I and ARB use for infectious, inflammatory or structural outcomes
Back to article page

Clinical Diabetes and Endocrinology

ISSN: 2055-8260

Contact us